GlassScriptPhysician profile
Kendra L Latty
NPI 1659763589
$1,200.94
in general payments reported to CMS, 2019-2025
14 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9.20 · 2024: $116 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $198.04 | 2025 | Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $143.95 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.92 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Abbvie INC. | $125.00 | 2025 | |
| Neurocrine Biosciences, INC. | $122.93 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.47 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $111.92 | 2025 | Austedo Xr |
| Indivior INC. | $36.60 | 2024 | Sublocade |
| Mylan Specialty L.P. | $24.33 | 2024 | Yupelri |
| Lilly USA, LLC | $23.16 | 2024 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $16.34 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Pfizer INC. | $15.08 | 2024 | |
| Genentech USA, INC. | $9.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Latty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.